Cargando…

Sorafenib- Taurine Combination Model for Hepatocellular Carcinoma Cells: Immunological Aspects

Sorafenib (Sor) is a multi-kinase inhibitor. It is recommended for the treatment of advanced hepatocellular carcinoma (HCC). However, Sor has severe and marked side effects. On the other hand, taurine (Tau) has been shown to enhance the therapeutic effects of cancer chemotherapy and also to enhance...

Descripción completa

Detalles Bibliográficos
Autores principales: Afifi, Ahmed M, El-Husseiny, Ahmed M, Tabashy, Reda H, Khalil, Mohamed A, El-Houseini, Motawa E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6982677/
https://www.ncbi.nlm.nih.gov/pubmed/31653148
http://dx.doi.org/10.31557/APJCP.2019.20.10.3007
_version_ 1783491343437266944
author Afifi, Ahmed M
El-Husseiny, Ahmed M
Tabashy, Reda H
Khalil, Mohamed A
El-Houseini, Motawa E
author_facet Afifi, Ahmed M
El-Husseiny, Ahmed M
Tabashy, Reda H
Khalil, Mohamed A
El-Houseini, Motawa E
author_sort Afifi, Ahmed M
collection PubMed
description Sorafenib (Sor) is a multi-kinase inhibitor. It is recommended for the treatment of advanced hepatocellular carcinoma (HCC). However, Sor has severe and marked side effects. On the other hand, taurine (Tau) has been shown to enhance the therapeutic effects of cancer chemotherapy and also to enhance the function of leukocytes. Here, we aimed to investigate the enhancing efficacy of Sor as well as minimizing its marked side effects by using Tau in combination in an immunological aspect. We evaluated the influence of Sor and Tau combination on the expression pattern of FOXP3 gene in HepG2 cells compared to peripheral blood mononuclear leukocytes (PBMCs) as control normal cells. Also, the levels of TGF-β and IL-10 released in culture media of both cells were determined. Our results revealed that, Tau reduced cytotoxicity of Sor on PBMC indicated by lactic dehyrogenase (LDH) release assay. In addition, Sor-Tau combination led to FOXP3 down-regulation in hepatic cancer cells (HepG2). The results showed also that, TGF-β levels decreased significantly in their culture media. In contrary, the cytokine increased in PBMCs culture media. Moreover, IL-10 was significantly elevated in the culture media of both cells. This study could open new avenues for the improvement of therapeutic efficacy of Sorafenib treated HCC patients by using Tau in combination.
format Online
Article
Text
id pubmed-6982677
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher West Asia Organization for Cancer Prevention
record_format MEDLINE/PubMed
spelling pubmed-69826772020-07-07 Sorafenib- Taurine Combination Model for Hepatocellular Carcinoma Cells: Immunological Aspects Afifi, Ahmed M El-Husseiny, Ahmed M Tabashy, Reda H Khalil, Mohamed A El-Houseini, Motawa E Asian Pac J Cancer Prev Research Article Sorafenib (Sor) is a multi-kinase inhibitor. It is recommended for the treatment of advanced hepatocellular carcinoma (HCC). However, Sor has severe and marked side effects. On the other hand, taurine (Tau) has been shown to enhance the therapeutic effects of cancer chemotherapy and also to enhance the function of leukocytes. Here, we aimed to investigate the enhancing efficacy of Sor as well as minimizing its marked side effects by using Tau in combination in an immunological aspect. We evaluated the influence of Sor and Tau combination on the expression pattern of FOXP3 gene in HepG2 cells compared to peripheral blood mononuclear leukocytes (PBMCs) as control normal cells. Also, the levels of TGF-β and IL-10 released in culture media of both cells were determined. Our results revealed that, Tau reduced cytotoxicity of Sor on PBMC indicated by lactic dehyrogenase (LDH) release assay. In addition, Sor-Tau combination led to FOXP3 down-regulation in hepatic cancer cells (HepG2). The results showed also that, TGF-β levels decreased significantly in their culture media. In contrary, the cytokine increased in PBMCs culture media. Moreover, IL-10 was significantly elevated in the culture media of both cells. This study could open new avenues for the improvement of therapeutic efficacy of Sorafenib treated HCC patients by using Tau in combination. West Asia Organization for Cancer Prevention 2019 /pmc/articles/PMC6982677/ /pubmed/31653148 http://dx.doi.org/10.31557/APJCP.2019.20.10.3007 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Afifi, Ahmed M
El-Husseiny, Ahmed M
Tabashy, Reda H
Khalil, Mohamed A
El-Houseini, Motawa E
Sorafenib- Taurine Combination Model for Hepatocellular Carcinoma Cells: Immunological Aspects
title Sorafenib- Taurine Combination Model for Hepatocellular Carcinoma Cells: Immunological Aspects
title_full Sorafenib- Taurine Combination Model for Hepatocellular Carcinoma Cells: Immunological Aspects
title_fullStr Sorafenib- Taurine Combination Model for Hepatocellular Carcinoma Cells: Immunological Aspects
title_full_unstemmed Sorafenib- Taurine Combination Model for Hepatocellular Carcinoma Cells: Immunological Aspects
title_short Sorafenib- Taurine Combination Model for Hepatocellular Carcinoma Cells: Immunological Aspects
title_sort sorafenib- taurine combination model for hepatocellular carcinoma cells: immunological aspects
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6982677/
https://www.ncbi.nlm.nih.gov/pubmed/31653148
http://dx.doi.org/10.31557/APJCP.2019.20.10.3007
work_keys_str_mv AT afifiahmedm sorafenibtaurinecombinationmodelforhepatocellularcarcinomacellsimmunologicalaspects
AT elhusseinyahmedm sorafenibtaurinecombinationmodelforhepatocellularcarcinomacellsimmunologicalaspects
AT tabashyredah sorafenibtaurinecombinationmodelforhepatocellularcarcinomacellsimmunologicalaspects
AT khalilmohameda sorafenibtaurinecombinationmodelforhepatocellularcarcinomacellsimmunologicalaspects
AT elhouseinimotawae sorafenibtaurinecombinationmodelforhepatocellularcarcinomacellsimmunologicalaspects